Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02887729
  4. Details
NCT02887729 Clinical Trial

Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease Clinical Trial

— GENKYST  

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02887729
Other study ID # GENKYST
Secondary ID
Status Recruiting
Phase N/A
First received August 30, 2016
Last updated September 1, 2016
Start date June 2010

Study information
Verified date August 2016
Source University Hospital, Brest
Contact Yannick Le Meur, MD PhD
Email yannick.lemeur@chu-brest.fr
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertésFrance: Ministère de l'Enseignement supérieur et de la RechercheFrance: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Study type Observational

Clinical Trial Summary

Genkyst is a regional cohort involving up to nephrologists working in private and public nephrology centers in the West of France. It registers clinical and molecular genetic data of all consenting patients with ADPKD from this area.

Recruitment information / eligibility
Status Recruiting
Enrollment 4000
Est. completion date
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- ADPKD patients followed in Nephrology centers in the West of France

- Age >17

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
France CHU Angers Angers
France AUB Brest Brest
France Centre Nephrologie et Dialyse d Armorique Brest
France CHU Brest Brest
France CH La Roche Sur Yon La Roche sur Yon
France CH Le Mans Le Mans
France ECHO dialyse Le Mans
France AUB Lorient Lorient
France CH Bretagne Sud Lorient
France AUB Morlaix Morlaix
France CHU Nantes Nantes
France CH Niort Niort
France CHU Poitiers Poitiers
France CH Centre Bretagne Pontivy
France AUB Quimper Quimper
France CHI de Cournouaille Quimper
France CHU Rennes Rennes
France ECHO Confluent Reze
France Centre Heliomarin de Roscoff Roscoff
France CH Yves LE FOLL Saint Brieuc
France ECHO Centre Ambulatoire Saint Herblain
France CH Saint Malo Saint Malo
France CH de Saint Nazaire Saint Nazaire
France CHU Tours Tours
France CH Bretagne Atlantique Vannes
France ECHO Vannes Vannes

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Clinical description of the patient at the inclusion day No
Secondary Genetic analysis at the inclusion day No
See also
  Status Clinical Trial Phase
Completed NCT02933268 - High Water Intake in Polycystic Kidney Disease N/A
Completed NCT00759369 - Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT00598377 - Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT01039987 - Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease N/A
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05193981 - A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Completed NCT03487913 - The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 2
Not yet recruiting NCT06435858 - Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Phase 4
Recruiting NCT05190744 - PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration Phase 2
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Recruiting NCT04344769 - Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruiting NCT02848521 - A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
Completed NCT01451827 - 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT01210560 - Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Phase 2
Completed NCT01336972 - Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT02134899 - The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients Phase 3
Active, not recruiting NCT02729662 - Efficacy of Tolvaptan on ADPKD Patients N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05288998 - Intrarenal Microvasculature in ADPKD
Recruiting NCT04939935 - Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Phase 3